USPTO serial 79330074
SYNENDOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 22, 2023
- Examiner
- MANCA, ALBERTO I
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYNENDOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Catherine F. Hoffman
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell, & Berkowitz, PC200 East Broward Blvd, Suite 2000Ft. Lauderdale, FL 33301United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; pharmaceutical products for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medical preparations and substances for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; medical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; veterinary preparations and substances for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; veterinary preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; sanitary preparations for medical use; medicines for pharmaceutical use for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; medicines for pharmaceutical use for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medicines for human medicine for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medicines for human medicine, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; medicines for human medicine, namely, medicines for treating biochemical imbalances in vivo; chemical-pharmaceutical preparations, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for pharmaceutical use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for veterinary use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use for treating biochemical imbalances in vivo; chemical preparations for veterinary use for treating biochemical imbalances in vivo; diagnostic substances, preparations and agents for medical use | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, analysis, testing in the fields of pharmaceuticals, biopharmaceuticals, chemistry, biology, biochemistry; industrial analysis services, namely, industrial analysis in the fields of pharmaceuticals, biopharmaceuticals; industrial research services in the fields of pharmaceuticals, biopharmaceuticals; scientific research and development; scientific research; scientific analysis, namely, biological analysis, biochemical analysis, chemical analysis; conducting chemical and biological analyses for scientific purposes; conducting medical analysis for scientific purposes, namely, biological analysis, biochemical analysis, chemical analysis, blood analysis; medical research; pharmaceutical research; research in the fields of chemistry and biology; biotechnological research services; providing medical and scientific research information, namely, providing information and data with respect to medical and veterinary research and development; providing information with respect to medical and scientific research in the field of pharmaceutical products; providing scientific information on research in the field of pharmaceutical products and biomedicine | ACTIVE | — |
| 044 | Medical services; veterinary services; hygienic care for human beings; medical and pharmaceutical consultancy services; medical tests for diagnostic or treatment purposes; conducting of medical examinations; consultations regarding pharmacology; pharmaceutical consulting, namely, consultant and information services relating to pharmaceutical products; conducting of chemical, medical and biological analyses for medical diagnosis being medical diagnostic testing services; consultancy and information services relating to medical products being pharmaceutical consultation services; medical analysis services relating to the treatment of patients; medical consultancy services; pharmacy advice being pharmaceutical consultation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Synendos Therapeutics AG
- Other trademarks owned by Synendos Therapeutics AG
- Other trademarks owned by Synendos Therapeutics AG
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SYNENDOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 26, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 26, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 26, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 26, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 11, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 22, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 22, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 22, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 22, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 22, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 19, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 6, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 6, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 6, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 31, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 31, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 17, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 17, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 17, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 1, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 1, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 1, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 1, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 1, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 25, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 24, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 8, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 4, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |